Table 2.
Univariate analysis for predicting EHM in the training cohort.
| Variable | EHM group (n = 320) | Non-EHM group (n = 136) | p-Value |
|---|---|---|---|
| Age, years | 53.83 (46.82, 63.32) | 53.42 (48.15, 62.69) | 0.959 |
| Sex | 0.511 | ||
| Male | 255 (79.7%) | 112 (82.4%) | |
| Female | 65 (20.3%) | 24 (17.6%) | |
| History of diabetes | 51 (15.9%) | 15 (11.0%) | 0.173 |
| History of cirrhosis | 219 (68.4%) | 94 (69.1%) | 0.886 |
| History of smoke | 94 (29.4%) | 41 (30.1%) | 0.869 |
| History of drink | 70 (21.9%) | 30 (22.1%) | 0.965 |
| BMI | 22.66 (20.57, 24.91) | 22.59 (20.67, 24.83) | 0.742 |
| Child-Pugh | 0.158 | ||
| A | 179 (55.9%) | 66 (48.5%) | |
| B | 127 (39.7%) | 59 (43.4%) | |
| C | 14 (4.4%) | 11 (8.1%) | |
| WBC, ×109/L | 5.03 (3.74, 6.58) | 5.37 (4.12, 7.64) | 0.053 |
| NE, % | 63.70 (55.96, 73.45) | 69.50 (59.03, 76.50) | 0.001 |
| HB, g/L | 144.50 (126.00, 160.00) | 139 (120.25, 157.00) | 0.044 |
| PLT, ×109 | 125.00 (79.00, 177.75) | 124.5 (79.50, 188.50) | 0.711 |
| ALT, U/L | 63.00 (35.00, 144.50) | 77.00 (43.00, 163.00) | 0.031 |
| AST, U/L | 76.50 (45.00, 170.00) | 104.50 (64.00, 242.00) | 0.002 |
| TP, g/L | 63.30 (58.00, 68.00) | 64.00 (57.70, 70.00) | 0.427 |
| ALB, g/L | 33.45 (30.43, 37.00) | 32.00 (28.10, 36.78) | 0.039 |
| GLO, g/L | 29.00 (25.60, 32.50) | 31.20 (26.33, 34.88) | 0.005 |
| TBIL, μmol/L | 25.35 (16.05, 44.00) | 31.60 (20.05, 52.70) | 0.007 |
| DBIL, μmol/L | 11.38 (6.60, 19.08) | 13.20 (8.33, 23.17) | 0.038 |
| ALP, U/L | 133.00 (89.00, 217.75) | 170.00 (110.25, 297.00) | 0.000 |
| Cr, μmol/L | 58.00 (51.00, 66.13) | 57.00 (50.00, 66.75) | 0.603 |
| CHE, U/L | 3563.00 (2571.50, 5067.00) | 2966.00 (2001.00, 4229.00) | 0.001 |
| INR | 1.13 (1.02, 1.26) | 1.18 (1.06, 1.34) | 0.002 |
| TT, s | 19.6 (17.70, 21.00) | 19.40 (18.00, 21.00) | 0.658 |
| DD, mg/L | 3.30 (1.53, 6.78) | 3.80 (2.63, 7.70) | 0.019 |
| APTT, s | 35.95 (31.60, 43.20) | 37.45 (32.65, 48.38) | 0.066 |
| FIB, g/L | 3.21 (2.30, 4.21) | 3.33 (2.41, 4.36) | 0.351 |
| PT, s | 13.60 (12.20, 15.30) | 14.1 (12.72, 15.98) | 0.004 |
| AFP, ng/ml | 246.34 (12.16, 2000.00) | 370.29 (17.92, 2000.00) | 0.507 |
| CEA ≥5 ng/ml | 30 (9.38%) | 17 (12.5%) | 0.637 |
| CA19-9 ≥35 U/ml | 38 (11.88%) | 17 (12.5%) | 0.770 |
| HBsAg, positive | 231 (76.7%) | 95 (72.5%) | 0.348 |
| Anti-HCV, positive | 9 (3.5%) | 6 (5.3%) | 0.417 |
| Tumor number | 4 (2, >4) | 4 (4, >4) | 0.001 |
| Tumor sizes, cm | 7.00 (4.00, 10.60) | 9.2 (5.91, 11.82) | 0.000 |
| Vascular invasion | 115 (35.9%) | 70 (51.5%) | 0.002 |
| Tumor location | 0.027 | ||
| Left lobe | 36 (11.3%) | 6 (4.4%) | |
| Right lobe | 145 (45.3%) | 57 (41.9%) | |
| Bilateral lobe | 139 (43.4%) | 73 (53.7%) |
BMI, Body Mass Index; WBC, White Blood Cell Count; NE, Neutrophil; HB, Hemoglobin; PLT, Platelet Count; ALT, Alanine Amiotransferase; AST, Aspartate Aminotransferase; TP, Total Protein; ALB, Albumin; GLO, Globulin; TBIL, Total Bilirubin; DBIL, Direct Bilirubin; ALP, Alkaline Phosphatase; Cr, Creatinine; CHE, Cholinesterase; INR, International Normalized Ratio; TT, Thrombin Time; DD, D-Dimer; APTT, Activated Partial Thromboplastin Time; FIB, Fibrinogen; PT, Prothrombin Time; AFP, α-Fetoprotein; CEA, Carcinoembryonic Antigen; CA19-9, Carbohydrate Antigen 19-9; HBsAg, Hepatitis B Surface Antigen; Anti-HCV, Anti-Hepatitis C Virus Antibody.